98%
921
2 minutes
20
Mycotoxin contamination frequently causes considerable food safety problems. Unfortunately, for on-site mycotoxin detection, the experimental continuity and the stability of the results are affected by human operation in the sample pretreatment process, which brings a series of errors and further affects the experiment. Considering that, a centrifugal microfluidic chip is developed for the continuous automatic operation of each preprocessing step, which can simultaneously pretreat ochratoxin A (OTA), deoxynivalenol (DON), and aflatoxin B1 (AFB1) with high throughput under optimal conditions. More importantly, the time-series impedance method is proposed for detection, which amplifies the signal difference of the three mycotoxins and provides better high temporal resolution. The whole on-chip pretreatment and detection took only 15 min. To further improve the advantage of the proposed sensor, the MXene@AuNPs modified electrode is proposed to obtain superb detection performance with high sensitivity. The standard curves of the three mycotoxins are established for accurate quantitative analysis. Variances of OTA, DON, and AFB1 standard curves are 0.9839, 0.9888, and 0.9793, respectively. The detection limits of OTA, DON, and AFB1 are 7.1 ng/L, 1.24 μg/L, and 11.8 ng/L. The average recovery of this method ranges from 94.0 to 106.1%, indicating good reliability and reproducibility. Moreover, the developed method exhibits negligible cross-reactions with other mycotoxins. This technique can be used for the early detection of mycotoxins, with great prospects and potential application for on-site instant detection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.analchem.5c00437 | DOI Listing |
ACS Sens
September 2025
METU MEMS Center, Ankara 06530, Türkiye.
Cardiovascular diseases (CVDs) remain a leading cause of death, particularly in developing countries, where their incidence continues to rise. Traditional CVD diagnostic methods are often time-consuming and inconvenient, necessitating more efficient alternatives. Rapid and accurate measurement of cardiac biomarkers released into body fluids is critical for early detection, timely intervention, and improved patient outcomes.
View Article and Find Full Text PDFJ Alzheimers Dis
September 2025
Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.
View Article and Find Full Text PDFJ Med Screen
September 2025
Institute of Cardiovascular Science, University College London, London, UK.
It is claimed that polygenic risk scores will transform disease prevention, but a typical polygenic risk score for a common disease only detects 11% of affected individuals at a 5% false positive rate. This level of screening performance is not useful. Claims to the contrary are either due to incorrect interpretation of the data or other influences.
View Article and Find Full Text PDFJAMA Dermatol
September 2025
Department of Population Health, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Importance: Increasingly, strategies to systematically detect melanomas invoke targeted approaches, whereby those at highest risk are prioritized for skin screening. Many tools exist to predict future melanoma risk, but most have limited accuracy and are potentially biased.
Objectives: To develop an improved melanoma risk prediction tool for invasive melanoma.
JAMA
September 2025
Division of Surgery and Interventional Science, UCL, London, United Kingdom.
Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.
View Article and Find Full Text PDF